Globus Medical, Inc. recently acquired Nuvasive. It should bolster international opportunities and round out its product portfolio. Click for my GMED update.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or “the Company”) (NYSE: GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Jetzt den vollständigen Artikel lesen

Globus Medical Heralds New Dawn with ADIRA XLIF Plate System In an age where the boundaries of scientific and medical ingenuity seem ever-expansive, it is with great anticipation and fanfare that we herald the advent of Globus Medical Inc.''s latest innovation the ADIRA XLIF Plate System. The esteemed establishment, a paragon in the realm of musculoskeletal solutions, announced their commercial launch on the 21st of August in the year of Our Lord, 2024. This unveiling marks a significant milestone, being the Company''s inaugural product launch that aligns seamlessly with its broadened lateral interbody portfolio. Situated in the bucolic yet industrious precincts of Audubon, Pennsylvania, Globus Medical Inc. (NYSE: GMED) has long stood as a bastion of pioneering health solutions. However, the financial nuances of their recent quarterly performances paint a portrait that mingles triumphs with trials. In the second quarter of the current year, the Company manifested a return on assets (ROA) quantified at 0.81%.

Globus Medical launched the Adira extreme lateral interbody fusion plate system, according to an Aug. 21 news release.

Globus Medical''s (NYSE: GMED ) short percent of float has fallen 29.25% since its last report. The company recently reported that it has 4.83 million shares sold short , which is 4.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.42 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

NEW YORK, Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…

The law firm of Kirby McInerney LLP is investigating potential claims against Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED). The investigation concerns whether Globus Medical and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On August Jetzt den vollständigen Artikel lesen

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Globus Medical investments or would like Jetzt den vollständigen Artikel lesen

Law Offices of Howard G. Smith announces an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company’s possible violations of federal securities laws. On August 13, 2024, the FDA published a warning letter to Globus Medical regarding an inspection of the Company’s Class II Excelsius GPS (EGPS) surgical robot, stating Jetzt den vollständigen Artikel lesen

The Law Offices of Frank R. Cruz announces an investigation of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 13, 2024, the FDA published a warning letter to Globus Medical regarding Jetzt den vollständigen Artikel lesen